HEALIOS K.K.

Richard Kincaid, Executive Officer and Chief Financial Officer

Tokyo, Japan

(TSE:4593)

Virtual Presentation

Healios K.K. is a biotechnology venture leading the field of regenerative medicine and cell therapy. It was founded in 2011 and listed on the Tokyo Stock Exchange in 2015. Healios is currently conducting clinical trials for ischemic stroke in Phase II/III and Acute Respiratory Distress Syndrome in Phase II using allogeneic adult stem cells from bone marrow, taking advantage of Japanese attractive regulatory framework for regenerative medicine. Healios is also developing iPSC regenerative medicine products in next-generation immunotherapy, the ophthalmology field, and liver disease. Furthermore, Healios is aiming to establish Universal Donor Cells, which are next-generation iPS cells created with gene editing technology.

www.healios.co.jp



By using this website you agree to accept our Privacy Policy and Terms & Conditions